OP0252 FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY
Yeoh S, Gianfrancesco M, Lawson-Tovey S, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Schaefer M, Richez C, Hachulla E, Holmqvist M, Scirè C, Hasseli R, Jayatilleke A, Hsu T, D’Silva K, Pimentel-Quiroz V, Vasquez del Mercado M, Katsuyuki Shinjo S, Reis Neto E, Rocha L, Montandon A, Jordan P, Sirotich E, Hausmann J, Liew J, Jacobsohn L, Gore-Massy M, Sufka P, Grainger R, Bhana S, Wallace Z, Robinson P, Yazdany J, Machado P. OP0252 FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY. Annals Of The Rheumatic Diseases 2022, 81: 165-166. DOI: 10.1136/annrheumdis-2022-eular.3235.Peer-Reviewed Original ResearchIdiopathic inflammatory myopathiesIdiopathic inflammatory myopathy patientsHigh disease activityDisease activityOdds ratioGrant/research supportAstra ZenecaInflammatory myopathiesSynthetic DMARDsCOVID-19 severity scaleCOVID-19 outcomesBristol-Myers SquibbMultivariate logistic regression analysis of factorsBoehringer IngelheimDisease-modifying anti-rheumatic drugsIIM casesSanofi GenzymeAssociated with worse outcomesFactors associated with severe COVID-19 outcomesMultivariate logistic regression analysisExposure to rituximabOutcomes of patientsConventional synthetic DMARDsAnti-rheumatic drugsLogistic regression analysis of factors